UCB, a global biopharmaceutical company, today announced it will present 24 abstracts from its expansive neurology portfolio, regarding rare epilepsies Dravet syndrome (DS) and Lennox-Gastaut syndrome ...

Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those ...

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...

More than 500 members of the myasthenia gravis (MG) rare disease community will come together this week in-person and ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

HOUSE, PA — Johnson & Johnson presented new data on its investigational treatment, nipocalimab, at the 2025 American Academy ...

Kyverna Therapeutics, Inc. ( ($KYTX) ) has released its Q4 earnings. Here is a breakdown of the information Kyverna Therapeutics, Inc. presented ...

This CME program is designed to enhance neurologists' understanding and management of generalized myasthenia gravis (gMG). Participants will explore how comprehensive assessment of disease burden ...

Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Aligned with the U.S. Food and Drug Administration (FDA) ...